In vitro evaluation of potentially effective gemcitabine-combination regimens for pancreatic adenocarcinoma;In-vitro-evaluierung potentiell effektiver gemcitabine- kombinationstherapien beim exokrinen pankreas-karzinom

Acta Medica Austriaca

Volumn 26, Issue 3, 1999, Pages 93-100

  Kreil, Anna ^a   Bauer, J ^a   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Gemcitabine; In vitro anticancer drug screening; Pancreatic cancer

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCAR; GEMCITABINE; MITOMYCIN C; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032850328     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aapro MS, Alberts DS, Salmon SE: Interaction of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against tumors in clonogenic assays. Cancer Chemother Pharmacol 10:161-166, 1983.
2. Abruzzese JL, Grunewald R, Weeks EA, et al.: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991.
3. Alberts DS, Chen HSG, Salmon SE: In vitro drug assay: pharmacologic considerations. In: Cloning of human stem cells. Salmon SE (eds.), Alan R Liss, New York. pp. 197-207, 1980.
4. Anderson H, Thatcher N, Walling J, Hansen H, Mejdahl P: A phase I study of 24 hour infusion of gemcitabine in patients with previously untreated, locally advanced non small cell lung cancer. Proc Am Soc Clin Oncol 13: 348, 1994 (abstract).
5. Arning M, Blatter J: Gemcitabine in solid tumors - present status and further development. Onkologie 20:297-304, 1997.
6. Braakhuis BJM, Ruiz van Haperen VWT, Bowen E, Veerman G, Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 22 (Suppl. 11):42-46, 1995.
7. Brown T, O'Rourke T, Burris H: A phase I trial of gemcitabine (LY 188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol 10:115, 1991 (abstract).
8. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15:2403-2413, 1997.
9. Cascinu S, Siva RR, Barni S, Labianca R, Frontini L, Pancera G, et al.: Gemcitabine (GEM; and 5-fluorouracil (5-FU) in advanced pancreatic cancer: a GISCAD phase II study. Proc Am Soc Clin Oncol 17:264a, 1998 (abstract).
10. Casper ES., Green MR., Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al.: Phase II trial of gemcitabine (2′,2′-difluorodeoxy-cytidine) in patients with adenocarcinoma of the pancreas; Invest New Drugs 12:29-34, 1994.
11. Cehn WH: Human pancreatic adenocarcioma: in vitro and in vivo morphology of a new tumor line established from ascites. In vitro 18:24-34, 1982.
12. Chang BK, Gutman R, Chou TC: Schedule-dependent interaction of adifluoromethylornithine and cis-diamminedihydrochloroplatinum (II) against human and hamster pancreatic cancer cell lines. Cancer Res 47:2247-2250, 1987.
13. Cortes-Funes H, Castellano D, Paz-Ares L, Gravalos C, Alonso S, Hitt R, et al.: A phase I-II study of gemcitabine (GEM) plus continuous infusion (CI) 5-fluorouracil (5-FU) in patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 17:265a, 1998 (abstract).
14. Csoka K, Liliemark J, Larrson R, Nygren P: Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22 (Suppl. 11): 47-53, 1995.
15. Fogh J: Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58:200-214, 1977.
16. Godefridus JP, Plunkett W. Gemcitabine: Status of preclinical studies und perspectives for future clinical applications of this novel nucleoside analog. Semin Oncol 22 (Suppl. 11): 1-3, 1995.
17. Grever MR, Chabner BA: Cancer drug discovery and development. In: Cancer principles De Vita VT Jr., Hellman S, Rosenberg SA (eds.), Lippincott-Raven Publishers, Philadelphia, 1997, pp. 385-395.
18. Heinemann V, Schulz L, Issles RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotid and deoxynucleotid metabolism. Semin Oncol 22:11-18, 1995.
19. Heineman V, Wilke H, Possinger K, Mergenthaler K, Clemens M, Konig HJ, et al.: Activity and tolerability of gemcitabine plus cisplatin in advanced pancreatic carcinoma. Eur J Cancer 33:274, 1997 (abstract).
20. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine ((2′,2′-difluorodeoxycytidine). Cancer Res 50:4417-4422, 1990.
21. Lieber M, Mazzetta J, Nelsen-Rees W, Kaplan M, Todaro G: Establishment of a continuous tumor-cell line (panc-1) from a carcinoma of the exocrine pancreas. Int J Cancer 15:741-747, 1975.
22. Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE: Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer Treat Rep 71:71-80, 1987.
23. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Visica D, et al.: Feasibility of a high-flux anticancer drug screen using a diverse panal of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766, 1991.
24. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJM: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (Suppl. 11):72-79, 1995.
25. Plunkett W, Huang P, Yi-Zheng Xu, Henemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanism of action, and selfpotentiation. Semin Oncol 22:3-10, 1995.
26. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7:347-353, 1996.
27. Scheithauer W, Clark GM, Moyer MP, Von Hoff DD: New Screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res 46:2703-2708, 1986.
28. Scheithauer W. Pankreaskarzinom. In: Klinisches Lehrbuch der Onkologie; H. Huber, W. Hiddemann, CR Bartram (eds.), Springer Verlag GmbH, Berlin/Heidelberg 1999 (in press).
29. Scheithauer W, Kornek GV, Raderer M, Hejna M, Valencak J, Miholic J, et al.: Phase II trial of gemcitabine, epirubicin, and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 1999 (in press).
30. Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220-228, 1996.
31. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, et al.: Characterisation of a new primary human pancreatic tumor line. Cancer Invest 4:15-23, 1986.
32. Tanis B, Clavel M, Guastalla J: Phase I study of gemcitabine (difluorodeoxycytidine; dFdC; LY 188 011) administered in a two-weekly schedule. Proc Am Assoc Cancer Res 31:207, 1990 (abstract).
33. Ulrich-Pur H, Kornek GV, Raderer M, Brugger S, Fiebiger W, Hejna M, et al.: Phase II Prüfung von hoch-dosiertem Gemcitabine beim metastasierten Pankreaskarzinom. Frühjahrstagung der Österr. Ges. f. Hämatologie und Onkologie, Innsbruck 15-17.4.1999 (in press).
34. Warshaw AL, Fernandez-del Castillo C: Pancreatic Cacinoma. N Engl j Med 326:455-465, 1992.
35. Weisenthal LM: Antineoplastic drug screening belongs in the laboratory and not in the clinic. J Natl Cancer Inst 84:466-469, 1991.